-

06:31:23 PM

AVIR Stock News

AVIR - Atea Pharmaceuticals Inc

09/26/22 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world's populations at-risk AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for treatment of dengue, showing potent in vitro and in vivo

RHEA-AI

neutral

09/13/22 7:00 AM

Nasdaq : AVIR

clinical trialcovid-19

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression Trial Expected to Initiate in Fourth Quarter 2022 Conference Call at 8:30 a.m. ET Today BOSTON, Sept. 13,

RHEA-AI

neutral

09/07/22 7:00 AM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals Announces Upcoming Investor Events

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 Registrational Trial in

RHEA-AI

neutral

08/08/22 4:05 PM

Nasdaq : AVIR

earnings

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data Demonstrate Bemnifosbuvir Retained Antiviral Activity Against Omicron Subvariant In Vitro Progressing

RHEA-AI

neutral

08/01/22 7:00 AM

Nasdaq : AVIR

conferencesearnings

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the

RHEA-AI

neutral

07/11/22 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals together with other members of the Atea

RHEA-AI

neutral

06/01/22 7:00 AM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and update at

RHEA-AI

neutral

05/10/22 6:30 AM

Nasdaq : AVIR

earnings

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical results from final analysis of Phase 2 hospitalized

RHEA-AI

negative

05/03/22 4:05 PM

Nasdaq : AVIR

conferencesearnings

Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to report financial results for the first

RHEA-AI

neutral

03/28/22 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today

RHEA-AI

neutral

1 2 3 4 5 6 Next

AVIR Data

IndustryPharmaceutical Preparation Manufacturing
Websiteateapharma.com
Security nameAtea Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees39
Tags
- Health Technology
- Pharmaceuticals: Major

About Atea Pharmaceuticals Inc

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, the Company has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, the Company is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) infection, and respiratory syncytial virus (RSV).